Effect of pitavastatin treatment on changes of plaque volume and composition according to the reduction of high-sensitivity C-reactive protein levels

Journal of Cardiology

Volumn 60, Issue 4, 2012, Pages 277-282

  Hong, Young Joon ^a   Jeong, Myung Ho ^a   Ahn, Youngkeun ^a   Kim, Sang Wook ^b   Bae, Jang Ho ^c   Hur, Seung Ho ^d   Ahn, Tae Hoon ^e   Rha, Seung Woon ^f   Kim, Kee Sik ^g   Chae, In Ho ^h   Kim, Jong Hyun ⁱ   Yun, Kyeong Ho ^j   Oh, Seok Kyu ^j  

^a Chonnam National University Medical School   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Konyang University College of Medicine   (South Korea)

^d Dongsan Medical Center   (South Korea)

^e Gachon University   (South Korea)

^f Korea University College of Medicine   (South Korea)

^g Catholic University of Daegu   (South Korea)

^h Seoul National University Bundang Hospital   (South Korea)

ⁱ Pusan Hanseo Hospital   (South Korea)

^j Wonkwang University Hospital   (South Korea)

more..

Author keywords

Acute myocardial infarction; Inflammation; Intravascular ultrasound; Plaque; Statin

Indexed keywords

C REACTIVE PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; PITAVASTATIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; ATHEROSCLEROTIC PLAQUE VOLUME; CLINICAL TRIAL; CORONARY ARTERY; DRUG EFFICACY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE;

C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; QUINOLINES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84866551714     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.04.003     Document Type: Article

References (45)

1. Noji Y., Higashikata T., Inazu A., Nohara A., Ueda K., Miyamoto S., Kajinami K., Takegoshi T., Koizumi J., Mabuchi H. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002, 163:157-164. Hokuriku NK-104 Study Group.
2. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., Grines C.L., DeMaria A.N. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080. REVERSAL Investigators.
3. Sacks F.M. High-intensity statin treatment for coronary heart disease. JAMA 2004, 291:1132-1134.
4. Topol E.J. Intensive statin therapy-a sea change in cardiovascular prevention. N Engl J Med 2004, 350:1562-1564.
5. Choi H., Cho D.H., Shin H.H., Park J.B. Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension. Circ J 2004, 68:297-303.
6. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007-2011.
7. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) Investigators.
8. Morrow D.A., Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003, 108:250-252.
9. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith S.C., Taubert K., Tracy R.P., Vinicor F., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
10. Sim D.S., Jeong M.H., Kang J.C. Current management of acute myocardial infarction: experience from the Korea Acute Myocardial Infarction Registry. J Cardiol 2010, 56:1-7.
11. Chen K.Y., Rha S.W., Li Y.J., Poddar K.L., Jin Z., Minami Y., Wang L., Kim E.J., Park C.G., Seo H.S., Oh D.J., Jeong M.H., Ahn Y.K., Hong T.J., Kim Y.J., et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009, 119:3207-3214.
12. Roberts W.L., Moulton L., Law T.C., Farrow G., Cooper-Anderson M., Savory J., Rifai N. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001, 47:418-425.
13. Mintz G.S., Nissen S.E., Anderson W.D., Bailey S.R., Erbel R., Fitzgerald P.J., Pinto F.J., Rosenfield K., Siegel R.J., Tuzcu E.M., Yock P.G. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS): a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001, 37:1478-1492.
14. Rodriguez-Granillo G.A., García-García H.M., McFadden E.P., Valgimigli M., Aoki J., de Feyter P., Serruys P.W. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol 2005, 46:2038-2042.
15. Nair A., Kuban B.D., Tuzcu E.M., Schoenhagen P., Nissen S.E., Vince D.G. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002, 106:2200-2206.
16. Zairis M.N., Manousakis S.J., Stefanidis A.S., Papadaki O.A., Andrikopoulos G.K., Olympios C.D., Hadjissavas J.J., Argyrakis S.K., Foussas S.G. C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. Am Heart J 2002, 144:782-789.
17. Kinjo K., Sato H., Ohnishi Y., Hishida E., Nakatani D., Mizuno H., Imai K., Nanto S., Naka M., Matsumura Y., Takeda H., Hori M. Impact of high-sensitivity C-reactive protein on predicting long-term mortality of acute myocardial infarction. Am J Cardiol 2003, 91:931-935. Osaka Acute Coronary Insufficiency Study (OACIS) Group.
18. Suleiman M., Aronson D., Reisner S.A., Kapeliovich M.R., Markiewicz W., Levy Y., Hammerman H. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med 2003, 115:695-701.
19. de Winter R.J., Bholasingh R., Lijmer J.G., Koster R.W., Gorgels J.P., Schouten Y., Hoek F.J., Sanders G.T. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc Res 1999, 42:240-245.
20. Blake G.J., Ridker P.M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003, 41:37S-42S.
21. James S.K., Armstrong P., Barnathan E., Califf R., Lindahl B., Siegbahn A., Simoons M.L., Topol E.J., Venge P., Wallentin L. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003, 41:916-924. GUSTO-IV-ACS Investigators.
22. van der Meer I.M., de Maat M.P., Bots M.L., Breteler M.M., Meijer J., Kiliaan A.J., Hofman A., Witteman J.C. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 2002, 22:838-842.
23. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
24. Jabs W.J., Theissing E., Nitschke M., Bechtel J.F., Duchrow M., Mohamed S., Jahrbeck B., Sievers H.H., Steinhoff J., Bartels C. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 2003, 108:1428-1431.
25. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., Davignon J., Erbel R., Fruchart J.C., Tardif J.C., Schoenhagen P., Crowe T., Cain V., Wolski K., Goormastic M., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565.
26. Okazaki S., Yokoyama T., Miyauchi K., Shimada K., Kurata T., Sato H., Daida H. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 2004, 110:1061-1068.
27. Hiro T., Kimura T., Morimoto T., Miyauchi K., Nakagawa Y., Yamagishi M., Ozaki Y., Kimura K., Saito S., Yamaguchi T., Daida H., Matsuzaki M. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009, 54:293-302. JAPAN-ACS Investigators.
28. Kodama K., Komatsu S., Ueda Y., Takayama T., Yajima J., Nanto S., Matsuoka H., Saito S., Hirayama A. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound - the TOGETHAR trial. Circ J 2010, 74:1922-1928.
29. Nicholls S.J., Borgman M., Nissen S.E., Raichlen J.S., Ballantyne C., Barter P., Chapman M.J., Erbel R., Libby P. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Curr Med Res Opin 2011, 27:1119-1129.
30. Araki T., Nakamura M., Utsunomiya M., Sugi K. Visualization of coronary plaque in type 2 diabetes mellitus patients using a new 40MHz intravascular ultrasound imaging system. J Cardiol 2012, 59:42-49.
31. Utsunomiya M., Hara H., Moroi M., Sugi K., Nakamura M. Relationship between tissue characterization with 40MHz intravascular ultrasound imaging and 64-slice computed tomography. J Cardiol 2011, 57:297-302.
32. Virmani R., Kolodgie F.D., Burke A.P., Farb A., Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 20:1262-1275.
33. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92:657-671.
34. Silva J.A., Escobar A., Collins T.J., Ramee S.R., White C.J. Unstable angina: a comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 1995, 92:1731-1736.
35. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995, 91:2844-2850.
36. Davies M.J., Richardson P.D., Woolf N., Katz D.R., Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993, 69:377-381.
37. Buja L.M., Willerson J.T. Role of inflammation in coronary plaque disruption. Circulation 1994, 89:503-505.
38. Hong M.K., Park D.W., Lee C.W., Lee S.W., Kim Y.H., Kang D.H., Song J.K., Kim J.J., Park S.W., Park S.J. Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. JACC Cardiovasc Interv 2009, 2:679-688.
39. Hattori K., Ozaki Y., Ismail T.F., Okumura M., Naruse H., Kan S., Ishikawa M., Kawai T., Ohta M., Kawai H., Hashimoto T., Takagi Y., Ishii J., Serruys P.W., Narula J. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovasc Imaging 2012, 5:169-177.
40. Zouki C., Beauchamp M., Baron C., Filep J.G. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest 1997, 100:522-529.
41. Torzewski M., Rist C., Mortensen R.F., Okumura M., Naruse H., Kan S., Ishikawa M., Kawai T., Ohta M., Kawai H., Hashimoto T., Takagi Y., Ishii J., Serruys P.W., Narula J. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000, 20:2094-2099.
42. Cermak J., Key N.S., Bach R.R., Balla J., Jacob H.S., Vercellotti G.M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82:513-520.
43. Verma S., Wang C.H., Li S.H., Dumont A.S., Fedak P.W., Badiwala M.V., Dhillon B., Weisel R.D., Li R.K., Mickle D.A., Stewart D.J. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913-919.
44. McMurray J.J., Kjekshus J., Gullestad L., Dunselman P., Hjalmarson A., Wedel H., Lindberg M., Waagstein F., Grande P., Hradec J., Kamenský G., Korewicki J., Kuusi T., Mach F., Ranjith N., et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009, 120:2188-2196.
45. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O'Shaughnessy C., Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38. The Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators.